Ladenburg starts Alterity at Buy, sees potential for MSA path as 'shortcut'
Ladenburg analyst Aydin Huseynov initiated coverage of Alterity Therapeutics with a Buy rating and $2 price target. ATH434's first indication being investigated is Multiple System Atrophy, or MSA, an orphan disease that shares similar features with Parkinson's disease, or PD, said Huseynov, who views the clinical development path for the MSA indication as "a shortcut to FDA approval." He likes Alterity because of its focus on MSA and what he sees as "a scientifically sound relation between iron chelation and the severity of MSA disease."
Some recent news about ATH
Life Bio is keeping dumping, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $8.75K | 1.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 63306661 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 28430837 | 21 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |